Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (41-50 of 299) with videos related to

Pageof 30
Sort By:
Nature Reviews. Clinical Oncology|October 8, 2014
An update on PARP inhibitors--moving to the adjuvant settingAmir Sonnenblick, Evandro de Azambuja, Hatem A Azim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2022
Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitivelyRoberto Salgado, Susan Fineberg, Alex De Caluwe, et al.
Nature Reviews. Clinical Oncology|August 2, 2017
HER2-positive breast cancer is lost in translation: time for patient-centered researchIsabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trialsElisa Agostinetto, Marcello Ceppi, Marco Bruzzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Reply to C. Fontanella et alHatem A Azim, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Nature Clinical Practice. Oncology|September 10, 2008
Facts and controversies in the use of trastuzumab in the adjuvant settingPhuong Dinh, Evandro de Azambuja, Fatima Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2009
HER-2 as a target for breast cancer therapyMichail Ignatiadis, Christine Desmedt, Christos Sotiriou, et al.
Targeted Oncology|May 7, 2009
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Evandro de Azambuja, Philippe L Bedard, Thomas Suter, et al.
Maturitas|December 15, 2015
Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countriesCaroline Antoine, Lieveke Ameye, Marianne Paesmans, et al.
Maturitas|August 27, 2014
Menopausal hormone therapy use in 17 European countries during the last decadeLieveke Ameye, Caroline Antoine, Marianne Paesmans, et al.
Pageof 30

Showing results (41-50 of 299) with videos related to

Sort By:
Pageof 30
Nature Reviews. Clinical Oncology|October 8, 2014
An update on PARP inhibitors--moving to the adjuvant settingAmir Sonnenblick, Evandro de Azambuja, Hatem A Azim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2022
Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitivelyRoberto Salgado, Susan Fineberg, Alex De Caluwe, et al.
Nature Reviews. Clinical Oncology|August 2, 2017
HER2-positive breast cancer is lost in translation: time for patient-centered researchIsabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trialsElisa Agostinetto, Marcello Ceppi, Marco Bruzzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Reply to C. Fontanella et alHatem A Azim, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Nature Clinical Practice. Oncology|September 10, 2008
Facts and controversies in the use of trastuzumab in the adjuvant settingPhuong Dinh, Evandro de Azambuja, Fatima Cardoso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2009
HER-2 as a target for breast cancer therapyMichail Ignatiadis, Christine Desmedt, Christos Sotiriou, et al.
Targeted Oncology|May 7, 2009
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Evandro de Azambuja, Philippe L Bedard, Thomas Suter, et al.
Maturitas|December 15, 2015
Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countriesCaroline Antoine, Lieveke Ameye, Marianne Paesmans, et al.
Maturitas|August 27, 2014
Menopausal hormone therapy use in 17 European countries during the last decadeLieveke Ameye, Caroline Antoine, Marianne Paesmans, et al.
Pageof 30